Everything below concerns circular dichroism. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-31. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
=== Removal from mounting sheet === Unattached specimens are removed from the herbaria sheet by humidifying it to make them pliable and removing the plant with a paper lifter (smooth wooden spatula). They are then placed to dry and flatten along with the original mounting sheet and written documentation (label and annotations). The specimen and original documents are then remounted to a new sheet using the original sheet as reference.
That the notochord evolved de novo in chordates by combining development programs in new ways. That the notochord derives from a homologous muscular structure, the axochord, that was present in annelid-like ancestors of the chordates. Supported by gene expression patterns and identification of said muscular structures in various inveterates, but cannot fully rule out the possibility of homoplasy. Deciding between these two scenarios (or possibly another yet to be proposed) should be facilitated by much more thorough studies of gene regulatory networks in a wide spectrum of animals.
== Definition == Vitamin B12 is a coordination complex of cobalt, which occupies the center of a corrin ligand and is further bound to a benzimidazole ligand and adenosyl group. Several related species behave similarly to function as vitamins. This collection of compounds is sometimes referred to as "cobalamins". These chemical compounds have a similar molecular structure, each of which shows vitamin activity in a vitamin-deficient biological system. They are referred to as vitamers having vitamin activity as a coenzyme, meaning that its presence is required for some enzyme-catalyzed reactions.
Sources: en.wikipedia.org
=== Haymarket grows === From the autumn of 1964, Haymarket set out aggressively to acquire magazines, approaching them from the list in the media directory BRAD. They acquired small, modestly profitable magazines for tape recorder and camera, and camping and caravan, enthusiasts, and using a loan from BPC bought a series of leisure and medical publications for £250,000 from a Canadian publisher, in competition with Thomson Group. In 1965 Heseltine's businesses had a turnover of around £700,000 per annum, and employed around 50 staff. Although the Opportunities for Graduates series continued to generate profits, Town magazine continued to lose money, hampered by the cost of printing (much more expensive at that time than nowadays) and by Heseltine's reluctance, for political reasons, to include pictures of nude girls or cartoons disrespectful of the Royal Family. Haymarket launched a bid for the British Institute of Management's magazine The Manager, again in competition with Thomson Group, in late 1965. It was envisaged that Haymarket would take a 25% stake, as would the Financial Times and The Economist, of both of which Crowther was also chairman. Over the weekend Heseltine, inspired by how Donald Stokes had once won a Scandinavian bus contract for British Leyland by building a model bus, had a team led by Labovitch prepare a 96-page mock copy of what they envisaged, mostly using text cut from The Economist.
=== Subclinical hypothyroidism === There is no evidence of a benefit from treating subclinical hypothyroidism in those who are not pregnant, and there are potential risks of unnecessary overtreatment. Untreated subclinical hypothyroidism may be associated with a modest increase in the risk of coronary artery disease when the TSH is over 10 mIU/L. There may be an increased risk for cardiovascular death. A 2007 review found no benefit of thyroid hormone replacement except for "some parameters of lipid profiles and left ventricular function". There is no association between subclinical hypothyroidism and an increased risk of bone fractures, nor is there a link with cognitive decline. American guidelines recommend that treatment should be considered in people with symptoms of hypothyroidism, detectable antibodies against thyroid peroxidase, a history of heart disease, or are at an increased risk for heart disease if the TSH is elevated but below 10 mIU/L. American guidelines further recommend universal treatment (independent of risk factors) in those with TSH levels that are markedly elevated; above 10 mIU/L because of an increased risk of heart failure or death due to cardiovascular disease. NICE recommends that those with a TSH above 10 mIU/L should be treated in the same way as overt hypothyroidism. Those with an elevated TSH but below 10 mIU/L who have symptoms suggestive of hypothyroidism should have a trial of treatment but intend to stop this if the symptoms persist despite normalization of the TSH.
==== Desiccation stress ==== Desiccation (drought) stress is defined as conditions where water becomes the growth limiting factor. MAAs have been reportedly found in high concentrations in many microorganisms exposed to drought stress. Particularly cyanobacteria species that are exposed to desiccation, UV radiation and oxidation stress have been shown to possess MAA's in an extracellular matrix. However it has been shown that MAAs do not provide sufficient protection against high doses of UV radiation.
Sources: en.wikipedia.org
The gastric juice also contains digestive enzymes produced by other cells in the gastric glands – gastric chief cells. Gastric chief cells secrete an inactivated pepsinogen. Once in the stomach lumen gastric acid activates the proenzyme to pepsin.
On September 15, 2012, David Wood, Deputy Director of the EBU Technology and Development Department (who chairs the ITU working group that created Rec. 2020), told The Hollywood Reporter that South Korea plans to begin test broadcasts of 4K UHDTV next year. Wood also said that many broadcasters have the opinion that going from HDTV to 8K UHDTV is too much of a leap and that it would be better to start with 4K UHDTV. In the same article, Masakazu Iwaki, NHK Research senior manager, said that the NHK plan to go with 8K UHDTV is for economic reasons since directly going to 8K UHDTV would avoid an additional transition from 4K UHDTV to 8K UHDTV. On October 18, 2012, the Consumer Electronics Association (CEA) announced that it had been unanimously agreed by the CEA's Board of Industry Leaders that the term "Ultra High-Definition", or "Ultra HD", would be used for displays that have a resolution of at least 8 megapixels with a vertical resolution of at least 2,160 pixels and a horizontal resolution of at least 3,840 pixels. The Ultra HD label also requires the display to have an aspect ratio of 16:9 or wider and to have at least one digital input that can carry and present a native video signal of 3840 × 2160 without having to rely on a video scaler. Sony announced they would market their 4K products as 4K Ultra High-Definition (4K UHD). On October 23, 2012, Ortus Technology Co., Ltd announced the development of the world's smallest 3840 × 2160 pixel LCD panel with a size of 9.6 inches (24 cm) and a pixel density of 458 px/in.
An infusion set is used with devices such as an insulin pump. The purpose of an infusion set is to deliver insulin under the skin, fulfilling a similar function like an intravenous line. It is a complete tubing system to connect an insulin pump to the pump user and as such includes a subcutaneous cannula, adhesive mount, quick-disconnect, and a pump cartridge connector. There are several types, styles, and sizes of infusion sets available, varying in cannula length, entry angle and in the length of tube connecting the cannula to the pump. The kind of choice of these options depends on a variety of factors, such as the patient's body fat percentage.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.